AWARD
A -- Preclinical Efficacy and Intermediate Endpoint Biomarkers
- Notice Date
- 9/24/2012
- Notice Type
- Award Notice
- NAICS
- 541711
— Research and Development in Biotechnology
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Blvd., EPS Suite 600, Rockville, Maryland, 20852
- ZIP Code
- 20852
- Solicitation Number
- N01CN25002-78
- Archive Date
- 10/5/2012
- Point of Contact
- Deborah A. Baca, Phone: (301) 435-3829, Susan K Hoffman, Phone: (301) 435-3799
- E-Mail Address
-
dbaca@mail.nih.gov, sh191h@nih.gov
(dbaca@mail.nih.gov, sh191h@nih.gov)
- Small Business Set-Aside
- N/A
- Award Number
- HHSN261201200013I_HHSN261201200014I_HHSN261201200015I_HHSN261201200016I
- Award Date
- 9/20/2012
- Awardee
- University of Oklahoma Health Science Ctr; SRI Int'l; Fox Chase Cancer Ctr; IIT Research Institute, University of Oklahoma Health Sciences Center<br />, 1000 Stanton L. Young Blvd., LIB 121<br />, Oklahoma City, OK 73117<br />, <br />, SRI International, Office 100-02<br />, 333 Ravenswood Avenue<br />, Menlo Park, CA 94025-3493<br />, <br />, The Research Institute of Fox Chase Cancer Center<br />, 333 Cottman Avenue<br />, Philadelphia, PA 19111<br />, <br />, IIT Research Institute<br />, 10 West 35th Street<br />, Chicago, IL 60616<br />, <br />, <br />, <br />, ,, United States
- Award Amount
- $9,950,000
- Description
- The purpose of these ID/IQ contracts is to evaluate the efficacy of potential chemopreventive regimens as well as to identifypharmacodynamic and or efficacy biomarkers which will enhance the development of these regimens for clinicaltrials. The studies will include, for example, evaluations of the efficacy of multiple chemopreventive regimens (newagents, altered dosing of agents, combinations of agents, vaccines, altered mechanisms of dosing) in multiple modelsof cancer in rodents. In addition the Contractor may have to examine a wide variety of potential biomarkers. TheContractor shall conduct intermediate endpoint assays in rodent tissues and may perform studies in NCI-suppliedhuman samples examining relevant intermediate endpoints. Task Orders can be either firm fixed-price or cost-reimbursement.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/N01CN25002-78/listing.html)
- Record
- SN02896908-W 20120926/120925004348-0aa79cea41056043763d98427bff8295 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |